These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25109614)

  • 21. [Nursing service for MS patients].
    Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16518890
    [No Abstract]   [Full Text] [Related]  

  • 22. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.
    Turner AP; Williams RM; Sloan AP; Haselkorn JK
    Rehabil Psychol; 2009 Feb; 54(1):116-21. PubMed ID: 19618711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence of adolescents to multiple sclerosis disease-modifying therapy.
    Thannhauser JE; Mah JK; Metz LM
    Pediatr Neurol; 2009 Aug; 41(2):119-23. PubMed ID: 19589460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.
    Tan H; Cai Q; Agarwal S; Stephenson JJ; Kamat S
    Adv Ther; 2011 Jan; 28(1):51-61. PubMed ID: 21153000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early use of interferon beta patients with multiple sclerosis.
    Bosley EB; Capildeo R
    Int J Clin Pract Suppl; 2002 Sep; (131):17-22. PubMed ID: 12564808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events.
    Brandes DW; Callender T; Lathi E; O'Leary S
    Curr Med Res Opin; 2009 Jan; 25(1):77-92. PubMed ID: 19210141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications.
    Mohr DC; Cox D; Merluzzi N
    Mult Scler; 2005 Apr; 11(2):182-5. PubMed ID: 15794392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
    Girouard N; Théorêt G
    Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
    Schwid SR; Thorpe J; Sharief M; Sandberg-Wollheim M; Rammohan K; Wendt J; Panitch H; Goodin D; Li D; Chang P; Francis G; ;
    Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent developments in interferon-based therapies for multiple sclerosis.
    Dumitrescu L; Constantinescu CS; Tanasescu R
    Expert Opin Biol Ther; 2018 Jun; 18(6):665-680. PubMed ID: 29624084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon after 10 years in patients with multiple sclerosis.
    Pozzilli C; Prosperini L; Sbardella E; Paolillo A
    Neurol Sci; 2006 Sep; 27 Suppl 5():S369-72. PubMed ID: 16998723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
    Zettl UK; Schreiber H; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Hecker M;
    Acta Neurol Scand; 2017 Aug; 136(2):116-121. PubMed ID: 27796033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of multiple sclerosis].
    Midgard R
    Tidsskr Nor Laegeforen; 2001 Aug; 121(19):2254. PubMed ID: 11571873
    [No Abstract]   [Full Text] [Related]  

  • 36. The BETACONNECT™ system: MS therapy goes digital.
    Limmroth V; Bartzokis I; Bonmann E; Kusel P; Schreiner T; Schürks M
    Neurodegener Dis Manag; 2018 Dec; 8(6):399-410. PubMed ID: 30278827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.
    Zettl UK; Bauer-Steinhusen U; Glaser T; Czekalla J; Hechenbichler K; Limmroth V; Hecker M
    Adv Ther; 2016 May; 33(5):834-47. PubMed ID: 27090116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.
    Boyko AN
    Expert Opin Biol Ther; 2010 Apr; 10(4):653-66. PubMed ID: 20218924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability, adherence, and patient outcomes.
    Ross AP
    Neurology; 2008 Dec; 71(24 Suppl 3):S21-3. PubMed ID: 19064871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seeing injectable MS therapies differently: they are more similar than different.
    Fox RJ; Arnold DL
    Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.